Our work discloses that celastrol, in a NF-κB inhibition/mTOR activation-related way, induces miR-223 in MCF-7 and PC3, and that down-regulating miR-223 could further reduce living cancer cells in samples treated with celastrol. The gene discussed is MTOR; the disease is cancer.